Nifty
:
25461.30
Sensex
:
83442.50
0.30 (0.00%)
9.61 (0.01%)
Nifty
Sensex
:
:
25461.30
83442.50
0.30 (0.00%)
9.61 (0.01%)

Strides Pharma Science Ltd.

Pharmaceuticals & Drugs - Global

Rating :
70/99

BSE: 532531 | NSE: STAR

NSE BSE
872.15
07-Jul-2025
  • Open
  • High
  • Low
  • Previous Close
  •  887.8
  •  889
  •  867.1
  •  885.25
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  316494
  •  277877790.45
  •  914
  •  394.2

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 8,028.29
  • 2.23
  • 10
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 9,687.12
  • 0.46%
  • 3.15

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 28.30%
  • 3.82%
  • 21.52%
  • FII
  • DII
  • Others
  • 28.32%
  • 11.92%
  • 6.12%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 12.98
  • 6.33
  • 9.68

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 12.35
  • 7.52
  • 26.41

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -18.90
  • -11.45
  • -35.27

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 6.07
  • -
  • -

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 2.20
  • 2.44
  • 2.67

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 14.96
  • 16.21
  • 14.34

Earnings Forecasts:

(Updated: 06-06-2025)
Description
2024
2025
2026
2027
Adj EPS
-7.76
390.5
51.9
67.8
P/E Ratio
-112.39
2.23
16.80
12.86
Revenue
4051
4565
5123
5719
EBITDA
743
954
1101
Net Income
-71
3593
479
625
ROA
-1.1
P/B Ratio
2.25
2.67
2.27
ROE
-3.26
17.1
19.1
FCFF
308
491
623
FCFF Yield
3.52
5.62
7.13
Net Debt
2199
BVPS
387.5
326.58
384.36

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 25
Mar 24
Var%
Dec 24
Dec 23
Var%
Sep 24
Sep 23
Var%
Jun 24
Jun 23
Var%
Net Sales
1,190.39
1,043.50
14.08%
1,153.67
1,005.77
14.71%
1,201.11
999.43
20.18%
1,087.50
929.99
16.94%
Expenses
972.52
839.19
15.89%
943.35
863.78
9.21%
965.30
846.30
14.06%
870.52
763.40
14.03%
EBITDA
217.87
204.31
6.64%
210.31
141.99
48.12%
235.81
153.13
53.99%
216.98
166.59
30.25%
EBIDTM
18.30%
19.58%
18.23%
14.12%
19.63%
15.32%
19.95%
17.91%
Other Income
11.98
-13.55
-
5.62
8.75
-35.77%
28.41
35.85
-20.75%
12.72
8.64
47.22%
Interest
50.32
71.10
-29.23%
52.18
69.71
-25.15%
82.15
78.59
4.53%
80.39
76.42
5.19%
Depreciation
48.86
47.94
1.92%
48.42
49.44
-2.06%
50.52
60.10
-15.94%
48.59
59.59
-18.46%
PBT
103.25
63.66
62.19%
112.89
21.52
424.58%
127.67
-114.64
-
96.98
33.25
191.67%
Tax
20.76
12.52
65.81%
23.80
15.74
51.21%
21.20
-7.44
-
16.86
9.68
74.17%
PAT
82.49
51.14
61.30%
89.09
5.78
1,441.35%
106.47
-107.20
-
80.12
23.57
239.92%
PATM
6.93%
4.90%
7.72%
0.57%
8.86%
-10.73%
7.37%
2.53%
EPS
8.92
1.98
350.51%
9.54
5.41
76.34%
10.14
-14.54
-
7.64
-0.77
-

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Net Sales
4,632.67
4,051.12
3,688.39
3,070.25
3,315.87
2,981.12
3,108.33
3,344.37
3,826.22
2,862.19
1,195.85
Net Sales Growth
16.44%
9.83%
20.13%
-7.41%
11.23%
-4.09%
-7.06%
-12.59%
33.68%
139.34%
 
Cost Of Goods Sold
1,897.45
1,640.50
1,626.88
1,502.32
1,332.79
1,122.48
1,085.20
1,378.84
1,281.17
1,502.29
560.49
Gross Profit
2,735.22
2,410.62
2,061.50
1,567.93
1,983.08
1,858.64
2,023.14
1,965.53
2,545.05
1,359.90
635.37
GP Margin
59.04%
59.51%
55.89%
51.07%
59.81%
62.35%
65.09%
58.77%
66.52%
47.51%
53.13%
Total Expenditure
3,751.69
3,318.01
3,303.09
3,091.76
2,689.06
2,470.90
2,811.65
3,108.66
3,309.30
2,481.62
967.00
Power & Fuel Cost
-
86.47
85.82
71.54
64.58
64.49
54.39
51.33
33.87
77.18
16.02
% Of Sales
-
2.13%
2.33%
2.33%
1.95%
2.16%
1.75%
1.53%
0.89%
2.70%
1.34%
Employee Cost
-
751.13
732.02
646.91
550.15
442.56
329.44
434.05
419.16
357.69
172.06
% Of Sales
-
18.54%
19.85%
21.07%
16.59%
14.85%
10.60%
12.98%
10.95%
12.50%
14.39%
Manufacturing Exp.
-
314.63
259.45
255.52
237.94
210.79
150.98
115.97
137.47
119.23
41.37
% Of Sales
-
7.77%
7.03%
8.32%
7.18%
7.07%
4.86%
3.47%
3.59%
4.17%
3.46%
General & Admin Exp.
-
253.44
232.21
223.67
191.73
191.89
150.10
194.38
172.63
198.71
86.25
% Of Sales
-
6.26%
6.30%
7.29%
5.78%
6.44%
4.83%
5.81%
4.51%
6.94%
7.21%
Selling & Distn. Exp.
-
224.81
263.65
331.30
223.22
137.07
111.22
208.85
161.12
129.57
61.37
% Of Sales
-
5.55%
7.15%
10.79%
6.73%
4.60%
3.58%
6.24%
4.21%
4.53%
5.13%
Miscellaneous Exp.
-
47.02
103.06
60.51
88.65
301.61
930.33
725.25
1,103.88
96.95
61.37
% Of Sales
-
1.16%
2.79%
1.97%
2.67%
10.12%
29.93%
21.69%
28.85%
3.39%
2.46%
EBITDA
880.97
733.11
385.30
-21.51
626.81
510.22
296.68
235.71
516.92
380.57
228.85
EBITDA Margin
19.02%
18.10%
10.45%
-0.70%
18.90%
17.12%
9.54%
7.05%
13.51%
13.30%
19.14%
Other Income
58.73
49.85
135.22
133.40
59.44
66.70
322.90
920.64
398.08
102.37
38.57
Interest
265.04
314.44
261.14
176.74
150.06
155.72
79.29
196.24
183.10
168.17
47.44
Depreciation
196.39
220.68
243.25
233.01
206.29
187.79
171.85
193.93
198.69
131.25
64.03
PBT
440.79
247.84
16.11
-297.88
329.90
233.42
368.44
766.17
533.20
183.50
155.95
Tax
82.62
31.59
-55.30
-178.26
31.65
17.91
14.49
21.41
51.19
42.45
147.60
Tax Rate
18.74%
53.72%
6010.87%
32.91%
8.48%
11.50%
3.71%
2.96%
10.30%
29.87%
99.35%
PAT
358.17
-124.83
-221.20
-460.21
352.32
143.62
370.31
681.31
399.38
113.21
1.57
PAT before Minority Interest
354.12
-148.53
-230.90
-474.25
341.61
137.82
375.57
701.18
445.58
99.68
0.98
Minority Interest
-4.05
23.70
9.70
14.04
10.71
5.80
-5.26
-19.87
-46.20
13.53
0.59
PAT Margin
7.73%
-3.08%
-6.00%
-14.99%
10.63%
4.82%
11.91%
20.37%
10.44%
3.96%
0.13%
PAT Growth
1,440.96%
-
-
-
145.31%
-61.22%
-45.65%
70.59%
252.78%
7,110.83%
 
EPS
38.85
-13.54
-23.99
-49.91
38.21
15.58
40.16
73.89
43.32
12.28
0.17

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Shareholder's Funds
2,125.56
2,212.26
2,359.23
2,776.66
2,527.42
2,648.70
2,463.66
2,748.82
2,657.87
1,144.92
Share Capital
91.90
90.30
89.79
89.68
89.56
89.55
89.50
89.42
89.35
59.62
Total Reserves
2,030.57
2,102.54
2,266.99
2,682.26
2,432.13
2,551.59
2,365.10
2,650.55
2,562.75
1,084.50
Non-Current Liabilities
621.44
1,210.30
965.72
1,264.45
813.65
2,342.88
2,067.29
2,048.67
2,760.03
285.79
Secured Loans
618.40
1,040.81
744.86
873.43
601.79
1,806.45
1,551.09
1,622.87
2,614.88
250.23
Unsecured Loans
53.10
98.98
90.77
9.15
2.12
0.06
0.23
14.84
12.13
17.16
Long Term Provisions
91.63
73.42
64.28
246.50
63.95
52.24
16.55
25.19
14.45
6.02
Current Liabilities
2,879.26
2,990.20
3,411.68
2,738.35
2,544.86
2,662.24
1,899.30
3,103.87
1,891.98
1,019.94
Trade Payables
851.59
982.34
1,071.52
1,134.20
797.75
888.99
712.07
774.09
775.40
234.41
Other Current Liabilities
341.57
527.89
697.18
421.00
354.49
248.12
129.98
819.08
347.93
502.47
Short Term Borrowings
1,574.15
1,330.76
1,496.53
1,023.84
1,228.78
1,339.02
944.39
1,393.96
700.48
203.03
Short Term Provisions
111.94
149.20
146.43
159.31
163.84
186.11
112.86
116.73
68.19
80.03
Total Liabilities
5,572.40
6,373.38
6,760.72
6,816.80
5,953.17
7,806.77
6,584.90
8,034.86
7,360.09
2,469.36
Net Block
1,853.18
2,298.42
2,333.45
2,151.13
2,025.85
3,570.13
2,903.00
2,909.03
2,678.68
701.36
Gross Block
2,873.18
3,324.82
3,231.69
2,841.28
2,534.38
4,049.05
3,229.03
3,186.12
2,825.43
1,080.55
Accumulated Depreciation
1,020.00
1,026.40
898.24
690.15
508.53
478.92
326.03
277.09
146.75
379.19
Non Current Assets
2,603.41
3,130.03
3,398.88
3,999.57
3,581.05
4,758.05
4,101.31
4,243.05
3,845.20
1,039.91
Capital Work in Progress
161.89
150.98
291.08
447.37
412.95
453.03
620.29
780.18
814.88
171.17
Non Current Investment
196.93
438.96
540.34
666.23
503.24
494.34
350.08
315.66
127.19
68.76
Long Term Loans & Adv.
256.13
217.18
210.58
185.80
210.82
223.69
197.22
222.56
201.83
96.72
Other Non Current Assets
123.38
11.91
10.26
549.04
428.19
16.86
30.72
15.62
22.62
1.91
Current Assets
2,969.00
3,135.25
3,361.83
2,817.23
2,372.11
3,048.72
2,483.59
3,791.82
3,514.89
1,429.44
Current Investments
105.76
50.84
0.00
99.41
118.97
284.75
311.48
1,279.54
1,213.76
561.29
Inventories
1,126.24
1,146.51
1,173.80
1,200.70
782.54
874.16
552.02
732.80
613.14
207.68
Sundry Debtors
1,141.87
1,299.40
1,207.30
1,110.59
931.69
987.18
882.18
995.91
1,032.97
389.96
Cash & Bank
191.17
315.96
187.35
179.76
237.10
516.65
303.33
329.48
311.59
146.88
Other Current Assets
403.96
169.21
647.90
98.22
301.81
385.98
434.59
454.09
343.44
123.64
Short Term Loans & Adv.
174.97
153.34
145.49
128.54
218.24
249.11
295.75
244.39
97.54
54.46
Net Current Assets
89.74
145.05
-49.84
78.89
-172.75
386.48
584.29
687.95
1,622.91
409.50
Total Assets
5,572.41
6,265.28
6,760.71
6,816.80
5,953.16
7,806.77
6,584.90
8,034.87
7,360.09
2,469.35

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Cash From Operating Activity
701.07
44.41
-257.81
481.44
204.79
60.05
187.07
288.14
73.25
83.40
PBT
-62.72
-267.63
-652.51
289.38
48.51
344.37
705.80
497.14
146.44
992.01
Adjustment
818.27
682.19
582.27
363.31
527.49
94.59
-274.51
190.92
345.56
-756.73
Changes in Working Capital
-78.73
-457.80
-189.90
-328.05
-326.23
-323.14
-190.66
-341.30
-341.71
-95.91
Cash after chg. in Working capital
676.82
-43.23
-260.14
324.64
249.76
115.82
240.63
346.76
150.29
139.37
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
24.25
87.64
2.33
156.80
-44.98
-55.76
-53.56
-58.62
-77.04
-55.97
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-150.25
302.47
-118.73
-520.82
1,306.16
-148.49
582.59
-686.69
-2,224.83
51.87
Net Fixed Assets
-75.44
-54.00
-61.59
-86.75
-167.06
-48.49
677.20
-236.66
-535.93
-66.57
Net Investments
-6.57
-92.01
62.72
-219.57
-17.15
-383.09
747.64
-143.27
-1,478.58
78.09
Others
-68.24
448.48
-119.86
-214.50
1,490.37
283.09
-842.25
-306.76
-210.32
40.35
Cash from Financing Activity
-693.32
-213.92
421.32
-15.80
-1,709.45
194.27
-1,015.69
338.21
2,943.94
-421.25
Net Cash Inflow / Outflow
-142.51
132.96
44.77
-55.18
-198.50
105.83
-246.03
-60.33
792.35
-285.98
Opening Cash & Equivalents
303.50
170.73
125.83
182.23
365.89
256.16
515.08
1,110.74
298.91
586.00
Closing Cash & Equivalent
161.02
303.50
170.73
125.83
182.23
365.89
256.16
515.08
1,110.74
298.42

Financial Ratios

Consolidated /

Standalone
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Book Value (Rs.)
230.95
242.83
262.48
309.09
281.55
294.94
274.26
306.41
296.83
191.91
ROA
-2.49%
-3.52%
-6.99%
5.35%
2.00%
5.22%
9.59%
5.79%
2.03%
0.04%
ROE
-6.88%
-10.15%
-18.49%
12.91%
5.34%
14.74%
27.00%
16.53%
5.25%
0.09%
ROCE
4.15%
-0.49%
-9.49%
11.17%
6.01%
8.65%
16.07%
10.75%
7.54%
10.92%
Fixed Asset Turnover
2.02
1.91
1.75
2.04
1.50
1.17
1.04
1.27
1.47
1.21
Receivable days
71.28
73.25
79.41
68.09
70.88
79.95
102.49
96.77
90.73
114.71
Inventory Days
66.36
67.80
81.35
66.13
61.20
61.00
70.11
64.20
52.34
58.37
Payable days
204.02
230.40
267.95
264.54
138.58
146.59
116.23
117.33
75.51
76.81
Cash Conversion Cycle
-66.38
-89.35
-107.20
-130.32
-6.50
-5.64
56.37
43.64
67.55
96.27
Total Debt/Equity
1.14
1.27
1.18
0.76
0.78
1.22
1.03
1.35
1.34
0.78
Interest Cover
0.63
-0.10
-2.69
3.49
2.00
5.92
4.68
3.71
1.85
4.13

Annual Reports:

FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
FY 2019
FY 2018
FY 2017
FY 2016
FY 2015

News Update:


  • Strides Pharma Science’s arm acquires identified ANDAs from Nostrum Laboratories, Inc, USA
    30th Apr 2025, 11:23 AM

    Two (out of the Four) ANDAs acquired are commercial products and is expected to be launched within 12 months

    Read More
  • Strides Pharma Science's arm incorporates wholly owned subsidiary
    11th Apr 2025, 15:00 PM

    Pivot Path shall focus on life sciences and manufacturing solutions with deep domain knowledge and cutting-edge technology capabilities

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.